Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones
Prnewswireยท2025-11-21 14:20
Accessibility StatementSkip Navigation BELLEVUE, Wash., Nov. 21, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), today announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG ("BCME"), a Swiss-based life sciences investment group and OSRH's largest shareholder, to explore a potential exclusive global licensing agreement for VXM01, Vaximm's first-in-class oral cancer immunotherapy platform. The term sheet establishes a six-month exclusivity period during ...